No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ANTX AN2 Therapeutics
- 2.560
- +0.020+0.79%
Close May 3 16:00 ET
- 2.560
- 0.0000.00%
Post 16:02 ET
76.36MMarket Cap-934P/E (TTM)
2.670High2.500Low168.39KVolume2.560Open2.540Pre Close432.99KTurnover1.48%Turnover RatioLossP/E (Static)29.83MShares22.22052wk High0.61P/B29.08MFloat Cap2.20052wk Low--Dividend TTM11.36MShs Float23.580Historical High--Div YieldTTM6.69%Amplitude2.200Historical Low2.571Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
OPI, RVNC and AQST Are Among After Hour Movers
Maintaining Caution: AN2 Therapeutics Hold Rating Amidst Epetraborole Trial Uncertainties
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOrgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increas
AN2 Therapeutics Price Target Announced at $6.00/Share by JMP Securities
AN2 Therapeutics Price Target Announced at $6.00/Share by JMP Securities
JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform
JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform.
Buy Rating Affirmed for AN2 Therapeutics Amidst Upcoming Catalysts and Strong Valuation Prospects
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg